DHODH protein levels in high-grade serous ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at a protein called DHODH in tumor tissue from people with high-grade serous ovarian cancer. It compares DHODH levels between those who had surgery first and those who had chemotherapy first, to see if it relates to treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-grade serous ovarian cancer.
- A sample of your tumor tissue is available for testing.
- Your treatment plan is known — either surgery first or chemotherapy first.
- Your medical records include follow-up information, such as how long it was before the cancer came back or your survival.
- You do not have other types or low-grade serous ovarian cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some high-grade ovarian cancers stop responding to standard chemotherapy. It aims to find ways to overcome that resistance, which may help improve treatment outcomes.
This study collects tumor samples from people newly diagnosed with advanced ovarian cancer to test for HRD, a genetic feature that may help doctors predict which treatments work best. The goal is to see if HRD testing can guide future treatment decisions for patients like you.
This study looks at how to best detect the HER2 protein in high-grade serous ovarian cancer. The goal is to improve treatment choices for people with this type of cancer.
This study is collecting tumor samples from women newly diagnosed with advanced ovarian cancer to check for a genetic marker called HRD. HRD testing can help doctors understand which treatments might work best for you.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
This trial uses a special imaging technique to study high-grade serous ovarian cancer. It aims to better understand the tumor to improve treatment. If you have advanced ovarian cancer and are scheduled for surgery, you may be eligible.
Hear when a new HGSOC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.